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ABSTRACT: We prepared 13 derivatives of N-(biphenyl-4′-yl)methyl (R)-2-acetamido-3-methoxypropionamide that diﬀered in
type and placement of a R-substituent in the terminal aryl unit. We demonstrated that the R-substituent impacted the
compound’s whole animal and cellular pharmacological activities. In rodents, select compounds exhibited excellent
anticonvulsant activities and protective indices (PI = TD50/ED50) that compared favorably with clinical antiseizure drugs.
Compounds with a polar, aprotic R-substituent potently promoted Na+ channel slow inactivation and displayed frequency (use)
inhibition of Na+ currents at low micromolar concentrations. The possible advantage of aﬀecting these two pathways to decrease
neurological hyperexcitability is discussed.
■ INTRODUCTION
(R)-N-Benzyl 2-acetamido-3-methoxypropionamide1 (lacosa-
mide, (R)-1) is a ﬁrst-in-class antiseizure drug (ASD) that is
marketed worldwide for adjunctive treatment of partial-onset
seizures.2 Whole animal pharmacological studies showed that
(R)-1 displayed potent anticonvulsant activity1,3 in the maximal
electroshock4 (MES), 6 Hz psychomotor,5 and hippocampal
kindled6 seizure models. Whole-cell, patch-clamp electro-
physiology studies indicated that (R)-1 reduced neuronal
hyperexcitability by a mechanism that was consistent with its
enhancing the transition of voltage-gated Na+ channels
(VGSCs) to the slow-inactivated state.7−9 Recent structure−
activity relationship studies demonstrated that modifying either
the N-benzyl10,11 or the O-methoxy12,13 sites in (R)-1 provided
analogues that retained excellent anticonvulsant activities.
Importantly, we found that the two N-(biphenyl-4′-yl)methyl
analogues, (R)-210 and (R)-3,11 when given orally to rats in the
MES model, exhibited activities that exceeded those of (R)-1
(Figure 1). We further showed that the IC50 value for Na
+
channel slow inactivation (the concentration at which half of
the Na+ channels transitioned to the slow-inactivated state) in
catecholamine A diﬀerentiated (CAD) cells14 was 29-fold lower
(more potent) for (R)-3 than for (R)-1 (Figure 1).15 While
these ﬁndings showed that introducing 4′-aryl substituents to
(R)-1 provided pharmacologically potent compounds, they also
showed that the 4′-aryl substituent aﬀected animal behavioral
neurotoxicity. Compound (R)-2 was signiﬁcantly more neuro-
toxic than (R)-1,10 but (R)-3 was not (Figure 1).11
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In this study, we report the synthesis and pharmacological
activity of 13 substituted N-(biphenyl-4′-yl)methyl (R)-2-
acetamido-3-methoxypropionamides (compound class (R)-A)
where the R-substituent in the terminal aryl unit was
systematically varied. The (R)-A’s R-substituent signiﬁcantly
impacted the compound’s whole animal and cellular
pharmacological activity. Numerous compounds with a polar,
aprotic R-substituent exhibited excellent anticonvulsant and
potent Na+ channel activities while producing minimal
behavioral neurotoxicities.
■ RESULTS
Compound Selection. Thirteen (R)-A derivatives, (R)-4−
(R)-16, containing diﬀerent R-substituents were synthesized
and evaluated in animal and cellular pharmacological models.
The compounds were divided into two groups. One set, (R)-
4−(R)-12, contained polar, aprotic R-substituents (i.e., F, Cl,
Br, I, CN, CF3, OCF3), and the second set, (R)-13−(R)-16,
contained polar, protic R-substituents (i.e., N(H)C(O)CH3,
CH2OH, CO2H, NH3
+Cl−). We expected that the CO2H
substituent in (R)-15 and the NH3
+Cl− substituent in (R)-16
were likely ionized at the physiological-like pH values used in
the evaluations. When the R-substituent was Br, I, CN, CF3,
N(H)C(O)CH3, CH2OH, CO2H, or NH3
+Cl−, we installed the
group at the 3″-position of the terminal aryl ring ((R)-7, (R)-8,
(R)-9, (R)-10, (R)-13, (R)-14, (R)-15, (R)-16); when the R-
substituent was F, Cl, or OCF3, we prepared both the 3″ ((R)-
3, (R)-5, (R)-11) and the 4″ ((R)-4, (R)-6, (R)-12)
regioisomers. We expected that the R-substituents would aﬀect
the compound’s biodistribution, anticonvulsant activities, and
ability to modulate Na+ channel function.
Chemistry. Compounds (R)-4−(R)-16 were prepared by
similar routes (Schemes 1−6) using the mixed anhydride
coupling (MAC) method16 and employing (R)-N-tert-butox-
ycarbonylserine ((R)-45), (R)-2-acetamido-3-hydroxypropionic
acid ((R)-69), or (R)-2-acetamido-3-methoxypropionic
acid10,12,17 ((R)-70) as the carboxylic acid component. The
choice of the carboxylic acid was dictated by the ease of
puriﬁcation of the intermediate products and the need to avoid
competing side reactions in the latter stages of the synthesis.
For compounds (R)-14−(R)-16, we removed the protecting
group in the ﬁnal step to facilitate the isolation of the desired
polar products.
To prepare compounds (R)-4−(R)-13, (R)-N-tert-butox-
ycarbonylserine ((R)-45) was coupled with the requisite
(biphenyl-4-yl)methylamine (29−39, 43, 44) using the MAC
reagents, isobutyl chloroformate (IBCF) and N-methylmorpho-
line (NMM), to give the amides (R)-46−(R)-55 (Scheme 3).
The crude (biphenyl-4-yl)methylamines were prepared by
Figure 1. Key pharmacological properties of (R)-1, (R)-2, and (R)-3.
Scheme 1. Preparation of (Biphenyl-4-yl)methylamines 29−39
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Suzuki coupling using tetrakis(triphenylphoshine)-
palladium(0).18 For 29−39, 4-bromobenzylamine (17) was
reacted with the commercially available arylboronic acids (18−
28) (Scheme 1), and for 43 and 44, p-aminomethylboronic acid
(40) was coupled with the appropriate 1,3-dihalobenzene (41,
42). The serine hydroxyl group in (R)-46−(R)-55 was
methylated (CH3I, Ag2O) to provide ethers (R)-56−(R)-65,
respectively. Deprotection of the tert-butoxycarbonyl group in
(R)-56−(R)-65 with acid (HCl/dioxane) followed by
acetylation (AcCl, Et3N) gave the desired products (R)-4−
(R)-13, respectively. For (R)-14 and (R)-15, we coupled (R)-
69 with (biphenyl-4-yl)methylamines 37 and 38 (Scheme 5),
and for (R)-16, we combined (R)-7010,12,17 with (3″-N-(tert-
butoxycarbonyl)aminobiphenyl-4′-yl)methylamine (39)
(Scheme 6). To facilitate the preparation of (R)-14−(R)-16,
we ﬁrst developed convenient synthetic procedures for (R)-69
and (R)-70 (Scheme 4). Commercially available D-serine benzyl
Scheme 2. Preparation of (Biphenyl-4-yl)methylamines 43 and 44
Scheme 3. Synthesis of Compounds (R)-4−(R)-13
Scheme 4. Synthesis of (R)-69 and (R)-70
Scheme 5. Synthesis of Compounds (R)-14 and (R)-15
Scheme 6. Synthesis of Compound (R)-16
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ester hydrochloride ((R)-66) was selectively converted to (R)-
2-N-acetamido-3-hydroxypropionate benzyl ester ((R)-67)
using 0.9 equiv of AcCl at −20 °C. Compound (R)-67 was
methylated (CH3I, Ag2O) at room temperature to give (R)-68,
Table 1. Structure−Activity Relationship for (R)-4−(R)-16a
aThe compounds were tested through the NINDS ASP. bThe compounds were administered intraperitoneally. ED50 and TD50 values are in
milligrams per kilogram. Numbers in parentheses are 95% conﬁdence intervals. A dose−response curve was generated for all compounds that
displayed suﬃcient activity. The dose−eﬀect for these compounds was obtained at the “time of peak eﬀect” (indicated in hours in the brackets).
cMES = maximal electroshock seizure test. d6 Hz = 6 Hz psychomotor seizure test. eTD50 value determined from the rotorod test.
fPI = protective
index (TD50/ED50) in the MES test.
gThe compounds were administered orally. ED50 and TD50 values are in milligrams per kilogram. Numbers in
parentheses are 95% conﬁdence intervals. A dose−response curve was generated for all compounds that displayed suﬃcient activity. The dose−eﬀect
for these compounds was obtained at the “time of peak eﬀect” (indicated in hours in the brackets). hTox = behavioral toxicity. iIC50, concentration at
which half of the Na+ channels have transitioned to a slow inactivated state. jReference 10. kND = not determined. lReference 11. mReference 1.
nReference 3. oReference 9. pReference 21.
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without racemization. Catalytic hydrogenation of (R)-67 and
(R)-68 using 10% Pd/C in methanol provided the desired acids
(R)-69 and (R)-70, respectively, which were used directly in
the MAC reaction without puriﬁcation.
The enantiomeric purity of (R)-4−(R)-13 was assessed by
detecting a single acetyl methyl peak and a single O-methyl
peak in the 1H NMR spectrum (CDCl3) for each compound
when a saturated solution of (R)-(−)-mandelic acid was
added.19 In the cases of (R)-14−(R)-16, their poor solubility in
CDCl3 prevented assessment of their optical purity by
1H
NMR. Thus, we demonstrated with 1H NMR the enantiomeric
purity of their immediate precursors (R)-73−(R)-75, respec-
tively.
In the Experimental Section, we report the details (synthetic
procedure, characterization) of the ﬁnal step for all compounds
evaluated in the anticonvulsant and cellular electrophysiology
studies. In Supporting Information, we provide the exper-
imental procedures and physical and spectroscopic properties
for all synthetic compounds prepared in this study.
Whole Animal Pharmacological Activity. Compounds
(R)-4−(R)-16 were tested for anticonvulsant activity at the
Anticonvulsant Screening Program (ASP) of the National
Institute of Neurological Disorders and Stroke (NINDS), U.S.
National Institutes of Health. Screening was performed using
the established protocols and procedures at the ASP described
by Stables and Kupferberg.20 We relied principally on two
rodent models to assess anticonvulsant activity, the MES4 and
the 6 Hz psychomotor5 seizure tests. The MES test is a model
for generalized tonic−clonic seizure and is thought to provide
an indication of a compound’s ability to prevent seizure spread
when all neuronal circuits in the brain are maximally active.
Correspondingly, the 6 Hz psychomotor test (32 mA) has been
used as a model for therapy-resistant limbic seizures. Previous
studies have shown that some compounds with minimal activity
in the MES test are eﬀective in the 6 Hz psychomotor model.5
The anticonvulsant data from the MES model4 (mice, ip; rat,
po) and psychomotor 6 Hz (32 mA) seizure test for therapy-
resistant limbic seizures5 (mice, ip) are summarized in Table 1
along with similar results obtained for (R)-1,1 (R)-2,10 (R)-3,11
and the ASDs phenytoin,21 phenobarbital,21 and valproate.21
For compounds that showed signiﬁcant activity, we report the
50% eﬀective dose (ED50) values from quantitative screening
evaluations. We also include the median doses for 50%
neurological impairment (TD50) in mice, using the rotorod
test,22 and the behavioral toxicity eﬀects observed in rats.23 The
protective index (PI = TD50/ED50) for the test compounds,
where possible, is also listed. Compounds (R)-2−(R)-6 and
(R)-11 and (R)-12 were evaluated in the subcutaneous
Metrazol (scMet) seizure model.24 No activity was observed
below 100 mg/kg (data not shown). Similarly, we observed no
activity in the scMet model for (R)-1 and structurally related
compounds.1,10−13
The R-substituent in (R)-4−(R)-16 markedly aﬀected the
observed anticonvulsant activity in the MES and 6 Hz seizure
tests (Table 1). We identiﬁed compounds with similar potency
compared with the parent compound in this series, the
unsubstituted N-(biphenyl-4′-yl)methyl (R)-2-acetamido-3-me-
thoxypropionamide ((R)-2),10 and the ASD (R)-1,1 while other
compounds showed little or no activity. The most potent
anticonvulsant compounds in the MES test contained a polar,
aprotic R-substituent (i.e., F ((R)-3, (R)-4); Cl ((R)-5, (R)-6);
Br ((R)-7); CF3 ((R)-10); OCF3 ((R)-11, (R)-12). The MES
ED50 values in mice (ip) ranged from 4.7 to 12 mg/kg and in
the rat (po) from 2.4 to <30 mg/kg. The corresponding ED50
values for (R)-2 in mice (ip) and rats (po) were 8.0 and 2.0
mg/kg,10 and for (R)-1 they were 4.5 and 3.9 mg/kg.1 We
observed little diﬀerences in the anticonvulsant activities in the
MES test in mice (ip) for the 3″-substituted F, Cl, and OCF3
compounds ((R)-3, (R)-5, (R)-11) compared with their 4″-
substituted regioisomers ((R)-4, (R)-6, (R)-12) (MES ED50
(mice, ip, mg/kg): (R)-3, 12; (R)-4, 6.1; (R)-5, 9.8; (R)-6, 12;
(R)-11, 4.7; (R)-12, 6.5). The 3″-CN substituted compound
((R)-9) exhibited only moderate activity in the MES seizure
model (mice, ip, mg/kg): (R)-9, 30−100). A pronounced
decrease in activity was seen for compounds (R)-13−(R)-16
containing a polar, protic R-substituent (i.e., N(H)C(O)CH3
((R)-13); CH2OH ((R)-14); CO2H ((R)-15); NH3
+Cl− ((R)-
16). Most of these compounds showed little activity in the
MES seizure model in mice (ip), with only (R)-14 exhibiting
modest activity (ED50, mice, ip, mg/kg: (R)-13, >300; (R)-14,
30−100; (R)-15, 100−300; (R)-16, ∼100).
We found that the neurotoxicity of (R)-A in the rotorod
(mice, ip) and behavioral (rat, po) tests varied with the nature
of the R-substituent and its position in the terminal aryl ring.
Many of the compounds ((R)-3, (R)-5−(R)-11, (R)-13−(R)-
16) were signiﬁcantly less neurotoxic in mice than the parent,
unsubstituted compound (R)-2 (TD50 = 11 mg/kg)
10 and
exhibited comparable or less neurotoxicity than the ASD (R)-1
(TD50 = 27 mg/kg).
1 Thus, the excellent activities in the MES
test (mice, ip) of (R)-3, (R)-5, (R)-6, and (R)-10 (ED50 (mg/
kg), (R)-3, 12; (R)-5, 9.8; (R)-6, 12; (R)-7, 12; (R)-10, 8.3)
coupled with their low neurotoxicities (TD50 (mg/kg), (R)-3,
50; (R)-5, 74; (R)-6, 82; (R)-7, 86; (R)-10, 50) provided
compounds with PIs (4.1−7.6) that were notably higher than
that of the parent, unsubstituted compound (R)-2 (PI = 1.4)
and that were similar to that of (R)-1 (PI = 6.0). When R was
either F or OCF3, we found that the 3″-derivative was less
neurotoxic than the 4″-substituted isomer (TD50 (mg/kg), (R)-
3 (3″-F), 50; (R)-4 (4″-F), 11; (R)-11 (3″-OCF3), 23; (R)-12
(4″-OCF3), 13) and provided higher PI values (PI, (R)-3 (3″-
F), 4.1; (R)-4 (4″-F), 1.8; (R)-11 (3″-OCF3), 4.9; (R)-12 (4″-
OCF3), 2.0); however, when R was Cl, there was little
diﬀerence in the neurotoxicity (TD50 (mg/kg), (R)-5 (3″-Cl),
74; (R)-6 (4″-Cl), 82) and in the PI values (PI, (R)-5 (3″-Cl),
7.6; (R)-6 (4″-Cl), 6.8) for the regioisomers. A drop in
neurotoxicity was observed for (R)-13−(R)-16, the four
compounds with polar, protic R-substituents (TD50 of 100 to
>300 mg/kg). These compounds showed moderate or little
protection in the seizure models. Taken together, these ﬁndings
demonstrated the importance of the R-substituent in (R)-A in
eliciting the optimal responses in the animal models. We found
that speciﬁc substituents and their placement in the terminal
aryl ring aﬀorded compounds ((R)-5 (3″-Cl), (R)-6 (4″-Cl),
(R)-7 (3″-Br), (R)-10 (3″-CF3), (R)-11 (3″-OCF3)) with
excellent anticonvulsant activities and improved PI values
compared with the parent, unsubstituted compound, (R)-2,10
in the mouse (ip). Similar results were observed in the rat (po)
(PI: (R)-2, 25;10 (R)-3, >210;11 (R)-5, >91; (R)-6, ∼78; (R)-
11, 34).
Three of the more active (R)-A compounds were tested in
the rat hippocampal seizure model (ip).6 This is a test of partial
complex or temporal lobe seizures, the most common and most
drug-resistant type of adult focal epilepsy.25−27 We obtained
ED50 values (mg/kg) for (R)-3, (R)-5, and (R)-11 of 13, 36,
and 1.7, respectively. The ED50 value for (R)-11 was 8-fold
lower than that for (R)-1 (14 mg/kg).3
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Whole-Cell, Patch-Clamp Electrophysiology. Com-
pounds of interest were characterized for their abilities to
interact with VGSCs by whole-cell patch-clamp electro-
physiological studies. In neurons, VGSCs are responsible for
action potential generation and propagation.28−30 These
channels undergo inactivation in response to activity over
two distinct time courses and mechanisms: fast inactivation
occurs over a few milliseconds, whereas slow inactivation
occurs over several hundred milliseconds. Inactivation is
reversible, but for a time, these channels are unable to produce
current in response to stimulus.31 The function of several
ASDs, such as carbamazepine and (R)-1, has been attributed to
their ability to inactivate VGSCs and reduce synaptic
activity.7−9,32 We assessed the ability of the (R)-A compounds
to alter Na+ channel kinetics of fast inactivation and slow
inactivation and also for frequency (use) dependence. These
studies were carried out in several cell models: CAD cells allow
for rapid characterization of compounds; rat cortical neurons
allow for characterization in cells related to those that generate
epileptic phenotypes in humans; and HEK293 cells allow for
characterization of activity on single VGSC isoforms.
A. 3″- and 4″-Polar, Aprotic Substituted N-(Biphenyl-4′-
yl)methyl (R)-Acetamido-3-methoxypropionamide Deriva-
tives in CAD Cells. We previously showed that (R)-3 inhibited
several parameters of VGSC activities in neuronal model CAD
cells.15 Here, we tested whether (R)-4−(R)-16 would result in
similar action. Initially, we focused on (R)-A compounds with
polar, aprotic R-substituents (i.e., R = F, Cl, Br, I, CF3, OCF3)
at either the 3″ or the 4″ position of the terminal aryl ring, since
these compounds exhibited the greatest anticonvulsant
activities (Table 1).
CAD cells are abundant and easy to use.14 These cells
express endogenous tetrodotoxin-sensitive Na+ currents that
display rapid activation and inactivation kinetics upon
membrane depolarization14 and likely comprise a majority of
NaV1.7 channels, with minor contributions by NaV1.1, NaV1.3,
and NaV1.9 channels.
9,33,34 Importantly, we earlier demon-
strated that the Na+ channel properties of (R)-1 in CAD cells9
were similar to those reported in cultured neurons and in
mouse N1E-115 neuroblastoma cells.7
First, we examined (R)-3,15 (R)-5, (R)-7, (R)-8, (R)-10, and
(R)-11, compounds with a 3″-polar, aprotic R-substituent (R =
Figure 2. Eﬀects of (R)-A compounds with a polar, aprotic substituent at the 3″-position on the steady-state, slow inactivation state of Na+ currents
in CAD cells. (A) Voltage protocol for slow inactivation. Currents were evoked by 5 s prepulses between −120 and +20 mV, and then fast-
inactivated channels were allowed to recover for 150 ms at a hyperpolarized pulse to −120 mV. The fraction of channels available at 0 mV was
analyzed. Representative current traces from CAD cells were taken in the absence (control, 0.1% DMSO) or presence of 10 μM (R)-11. The black
and red traces represent the currents evoked at −120 and −50 mV, respectively (also highlighted in the voltage protocol). (B−G) Summary of
steady-state, slow activation curves for CAD cells treated with 0.1% DMSO (control) or with various concentrations of the indicated compounds.
(H) The concentrations at which half of the channels have transitioned to the slow-inactivated state (see text for details), the SI IC50, are indicated.
Data are from four to seven cells per condition.
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F, Cl, Br, I, CF3, OCF3), for their ability to transition Na
+
channels to the slow-inactivated state. CAD cells were held at
−80 mV and conditioned to potentials ranging from −120 to
+20 mV (in +10 mV increments) for 5 s. Then fast-inactivated
channels were allowed to recover for 150 ms at a hyper-
polarized pulse to −120 mV, and then the fraction of channels
available was tested by a single depolarizing pulse, to 0 mV, for
15 ms (Figure 2A, left). Brief hyperpolarization to −120 mV
allows channel recovery from fast inactivation while limiting
recovery from slow inactivation such that the property of slow
inactivation can be isolated. Representative slow inactivation
traces, at −120 and −50 mV, from CAD cells treated with 0.1%
DMSO (control) or 10 μM (R)-11 are shown in Figure 2A
(right). At −50 mV, a majority of the channels undergo steady-
state inactivation that involves contributions from slow- and
fast-inactivating pathways.28,35 This voltage is also near the
resting membrane potential (RMP) and approaches the action
potential ﬁring threshold for CNS neurons,36 where slow
inactivation appears to be physiologically relevant during
sustained subthreshold depolarizations.37 Finally, changes in
Figure 3. Eﬀects of (R)-A compounds with a polar, aprotic substituent at the 3″-position on fast inactivation and steady-state activation state of Na+
currents in CAD cells. (A) Voltage protocol for fast inactivation (left) and activation (right). Representative families of currents in response to these
protocols are illustrated. (B−G) Representative Boltzmann ﬁts for steady-state fast inactivation and activation for CAD cells treated with 0.1%
DMSO (control) and various concentrations of the indicated compounds are shown. Values for V1/2, the voltage of half-maximal inactivation and
activation and the slope factors (k) were derived from Boltzmann distribution ﬁts to the individual recordings and were averaged to determine the
mean (±SEM) voltage dependence of steady-state inactivation and activation, respectively. The V1/2 and k of steady-state fast inactivation or
activation other than (R)-8 were not diﬀerent among any of the conditions tested (p > 0.05, one-way ANOVA). Data are from four to six cells per
condition.
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the Na+ channel availability near −50 mV can aﬀect the overlap
of Na+ current activating and inactivating under steady-state
conditions.28,38 For these reasons, we utilized −50 mV
conditioning pulses to compare pharmacological eﬀects on
slow inactivation and to develop concentration−response
curves and IC50 values for each tested compound (Figure
2B−G). The slow inactivation IC50 values are shown in Figure
2H and summarized in Table 1. Compared with the reported
IC50 calculated value of 85 μM for slow inactivation induced by
(R)-1,9 the IC50 values for these 3″-substituted (R)-A
compounds were considerably lower. For example, the IC50
values for (R)-3 and (R)-8 were 29- and 133-fold lower than
(R)-1. Collectively, these data indicate that these (R)-A
derivatives more eﬀectively induced Na+ channel transition to
a slow-inactivated state than did (R)-1.
A similar series of experiments were undertaken to
investigate the eﬀects of (R)-A compounds with polar, aprotic
substituents (R = F, Cl, OCF3) at the 4″-aryl site on Na+
current slow inactivation. We observed pronounced, concen-
tration-dependent slow inactivation for (R)-4, (R)-6, and (R)-
12 (Supporting Information, Figure S1B−D). As for the 3″-
substituted compounds, the IC50 values of slow inactivation
were calculated by ﬁtting the concentration responses of slow
inactivation against the V1/2 of slow inactivation (Table 1;
Supporting Information, Figure S1E). The IC50 values for (R)-
4, (R)-6, and (R)-12 were 101-, 708-, and 129-fold lower than
for (R)-1.
We next asked if the polar, aprotic (R)-A derivatives could
enhance steady-state fast inactivation in CAD cells. For these
studies we used a protocol (Figure 3A) designed to induce a
fast-inactivated state, similar to that previously described.33
Cells were held at −80 mV, stepped to inactivating prepulse
potentials ranging from −120 to −10 mV (in 10 mV
increments) for 500 ms. Then the cells were stepped to 0
mV for 20 ms to measure the available current. A 500 ms
conditioning pulse was used because it allowed all of the
endogenous channels to transition to a fast-inactivated state at
all potentials assayed. In Figure 3, we provide the steady-state,
fast inactivation curves of Na+ currents (representative family of
current traces shown in Figure 3A from control (0.1% DMSO)
and Figure 3B−G for (R)-A derivatives with a polar, aprotic 3″-
substituent). (R)-3-, (R)-5-, (R)-7-, (R)-8-, (R)-10-, and (R)-
11-treated CAD neurons were well ﬁtted with a single
Boltzmann function (R2 > 0.969 for all conditions). The V1/2
inactivation value for 0.1% DMSO-treated cells was −68.3 ±
3.1 mV (n = 5), which was signiﬁcantly diﬀerent from that of
(R)-8 (10 μM) treated cells (−76.5 ± 1.3 mV; n = 5; p < 0.05;
Student’s t-test; see Figure 3E). Compared with the ∼8.2 mV
shift in V1/2 of fast inactivation in the hyperpolarizing direction
observed in the presence of (R)-8, the shifts caused by the
other ﬁve compounds were not signiﬁcantly diﬀerent from
control (Figure 3B−D,F,G) (p < 0.05 vs 0.1% DMSO
(control); Student’s t-test). We also found that (R)-1 did not
aﬀect Na+ channel fast inactivation.9
The eﬀects of (R)-A derivatives with 4″-polar, aprotic
substituents (F, Cl, OCF3) on Na
+ current fast inactivation was
also investigated (Supporting Information, Figure S2). Steady-
state, fast inactivation curves of Na+ currents from 0.1%
DMSO- (control) and (R)-4-, (R)-6-, and (R)-12-treated CAD
cells were well ﬁtted with a single Boltzmann function (R2 >
0.989 for all conditions). The V1/2 inactivation value for 0.1%
DMSO-treated cells was not signiﬁcantly diﬀerent from any of
the conditions (p > 0.05; Student’s t-test; Supporting
Information Figure S2B−D).
Because changes in current amplitudes can result from
changes in channel gating, we tested whether the nine 3″- and
4″-polar, aprotic (R)-A derivatives ((R)-4−(R)-12) could alter
voltage-dependent activation properties of Na+ currents in
CAD cells. Activation changes for the (R)-A derivative treated
CAD cells were measured by whole-cell ionic conductances by
Figure 4. Eﬀect of (R)-A compounds with a polar, aprotic substituent at the 3″-position on frequency (use) dependent block of Na+ currents in
CAD cells. (A) The frequency dependence of the block was examined by holding cells at the hyperpolarized potential of −80 mV and evoking
currents at 10 Hz by 20 ms test pulses to −10 mV (inset middle). Representative overlaid traces are illustrated by pulses 1 and 30 for control
(predrug) and in the presence of (R)-5 (5 μM). (B−F) Summary of average frequency (use) dependent decrease in current amplitude (±SEM)
produced by control (0.1% DMSO) or by the presence of various concentrations of the indicated compounds (p > 0.05, one-way ANOVA with
Dunnett’s post hoc test). Data are from three to six cells per condition. As a comparison, a use-dependent block imposed by (R)-3 is also shown.15
Compounds (R)-3, (R)-5, (R)-10, and (R)-11 caused a signiﬁcant decrease (indicated by ∗) in current amplitude compared with 0.1% DMSO-
treated cells (control) (p < 0.05, one-way ANOVA with Dunnett’s post hoc test). Note the rapid frequency-dependent facilitation of the block by
(R)-3 and (R)-5, which was observed beginning as early as pulse 4. Data are from three to six cells per condition.
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comparing their midpoints (V1/2) and slope factors (k) in
response to changes in command voltage (Figure 3A, top
right). Representative traces in response to the voltage protocol
are shown in Figure 3A (bottom right). Boltzmann ﬁts for 0.1%
DMSO (control) and various concentrations of (R)-3, (R)-5,
(R)-7, (R)-8, (R)-10, and (R)-11 are shown in Figure 3B−G
and those for (R)-4, (R)-6, and (R)-12 in Supporting
Information, Figure S2B−D. An analysis of the six 3″-
substituted compounds ((R)-3, (R)-5, (R)-7, (R)-8, (R)-10,
(R)-11) V1/2 and k values showed that, with the exception of
two (R)-8 concentrations, there were no changes in the steady-
state activation properties of Na+ currents between CAD cells
treated with 0.1% DMSO (control) or with any of the tested
compounds (Figure 3C−G). The V1/2 steady-state activation
value for 0.1% DMSO-treated (control) cells was −12.8 ± 0.5
mV (n = 4), which was signiﬁcantly diﬀerent from that of (R)-
8-treated cells at 100 nM (−24.6 ± 3.9 mV, n = 4) and at 300
nM (−20.7 ± 2.4 mV, n = 5) (p < 0.05; Student’s t-test; see
Figure 3E). Similarly, we found that the V1/2 or k values for
steady state activation for 0.1% DMSO-treated (control) cells
were not signiﬁcantly diﬀerent from those of the 4″-substituted
(R)-A compound (10 μM) treated CAD cells ((R)-4, (R)-6,
and (R)-12; p > 0.05; Student’s t-test; Supporting Information
Figure S2B−D). These data indicate that, except for (R)-8,
polar, aprotic (R)-A derivatives did not aﬀect a closed channel’s
transition to an open conformation.
Finally, we tested whether (R)-4−(R)-12 could elicit a
frequency (use) dependent block of Na+ currents in CAD cells.
Use dependency represents an ability to bind more eﬃciently
to a channel undergoing repeated transitions between closed,
open, and inactivated conformations. The ability to block Na+
currents in an activity- or use-dependent manner is a useful
property for ASDs, since it allows for preferential decreases in
Na+ channel availability during high-frequency (seizure-like)
but not low-frequency ﬁring.39 Several theories have been
proposed to account for the complexities of use-dependent
inhibition, including the modulated receptor hypothesis,40
which postulates that the receptor on the Na+ channels can
exist in multiple conﬁgurations and the aﬃnity and binding
rates of drugs depend on channel’s state, which in turn can
depend on voltage. The response to voltage changes can be
viewed as reﬂecting voltage-sensitive shifts in equilibrium
between conducting, unblocked channels and nonconducting,
blocked channels. The modulated-receptor hypothesis postu-
lates shifts in equilibrium as the result of a variable-aﬃnity
receptor and modiﬁed inactivation gate kinetics in drug-
complexed channels. We tested compounds (R)-5, (R)-7, (R)-
8, (R)-10, and (R)-11 at a range of concentrations from below
to above the determined slow inactivation IC50 values. A train
of 30 test pulses (20 ms to −10 mV) was delivered from a
holding potential of −80 mV at 10 Hz (Figure 4A). The
available current in control cells (0.1% DMSO) and cells in the
presence of the (R)-A compounds was calculated by dividing
the peak current at any given pulse (pulseN) by the peak
current in response to the initial pulse (pulse1). Representative
currents elicited by the voltage protocol are illustrated for
control and 5 μM (R)-5-treated cells (Figure 4A). Compounds
(R)-5, (R)-10, and (R)-11 exhibited a statistically signiﬁcant
concentration-dependent frequency (use) inhibition of Na+
currents (Figure 4B,E,F) by the last pulse, compared with
control (0.1% DMSO). The peak current was ∼50% lower in
the presence of 5 μM (R)-5, ∼18% lower in the presence of 10
μM (R)-10, and ∼65% lower in the presence of 6 μM (R)-11.
These test concentrations were 7.1−7.6 times higher than their
slow inactivation IC50 values. By comparison, as we previously
reported, there was a 45% diminution of Na+ currents in the
presence of 15 μM (R)-3 (Figure 4B, purple circles), a
concentration that is 5.2 times higher than the slow inactivation
Figure 5. Eﬀects of (R)-A compounds with a polar, aprotic substituent at the 3″-position on steady-state, slow inactivation state of Na+ currents in
embryonic cortical neurons. (A) Voltage protocol for slow inactivation. Currents were evoked by 5 s prepulses between −100 and +20 mV (in +10
mV increments), and then fast-inactivated channels were allowed to recover for 1000 ms at a hyperpolarized pulse to −70 mV before testing for the
fraction of available channels for 20 ms at −10 mV. The fraction of channels available at −10 mV was analyzed. Shown are representative current
traces from cortical neurons in the absence (control, 0.1% DMSO) or presence of 10 μM (R)-5. The black and gray traces represent the currents
evoked at −100 and −50 mV, respectively (highlighted in the voltage protocol as thick, dashed line). (B) Summary of steady-state, slow-activation
curves for neurons treated with 0.1% DMSO (control) or 10 μM (R)-5. Signiﬁcant drug-induced slow inactivation was evident at voltages more
depolarizing than −80 mV in neurons treated with (R)-5. (C) Summary of the available current fraction at −50 mV for neurons treated with DMSO
(control) or 10 μM (R)-3, (R)-5, (R)-7, (R)-8, (R)-10, and (R)-11. Asterisks (∗) indicate statistically signiﬁcant diﬀerences in available current
fraction between control (0.1% DMSO) and the indicated compounds (p < 0.05, Student’s t-test). Data are from ﬁve to six cells per condition.
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IC50 value. Similarly, the traces for (R)-7 and (R)-8 (Figure
4C,D) suggested frequency (use) inhibition of the Na+ currents
at a 10 μM concentration, but the values did not reach
statistical signiﬁcance. We did not test these (R)-A compounds
at higher concentrations.
We also examined whether the three polar, aprotic 4″-
substituted derivatives (R)-4, (R)-6, and (R)-12 aﬀected
frequency (use) dependent block of Na+ currents using a
single concentration of 1 μM, a concentration at which near
maximal eﬀects on slow inactivation were observed (IC50
(μM): (R)-4, 0.82; (R)-6, 0.12; (R)-12, 0.66; Supporting
Information Figure S1). Only (R)-4 and (R)-6 exhibited small
but statistically signiﬁcant reduction in frequency (use)
dependent bock of Na+ currents; by the last pulse, compared
with control, the peak current was ∼15% lower in the presence
of 1 μM (R)-4 and ∼16% lower in the presence of 1 μM (R)-6
(Supporting Information, Figure S3B).
B. Polar, Aprotic and Polar, Protic N-(Biphenyl-4′-yl)-
methyl (R)-2-Acetamido-3-methoxypropionamide Deriva-
tives in Rat Embryonic Cortical Neurons. Next, we tested
many of the compounds with 3″-polar, aprotic R-substituents
(R = F, Cl, Br, I, CF3, OCF3) in rat embryonic cortical neurons.
These cells express channel subtypes (NaV1.1, NaV1.2, NaV1.3,
NaV1.6) that participate in seizure propagation,
41 and we
assumed contributions from all four CNS NaV isoforms to the
observed eﬀects. Slow inactivation, fast inactivation, steady-state
activation, and frequency (use) dependence of Na+ currents in
rat cortical neurons grown for 7−10 days in vitro were
examined using protocols described earlier.42 Because of the
reduced availability of cortical neurons and their viability under
the patch-clamp electrophysiology conditions, we used only 10
μM (R)-A compounds. Furthermore, because the CAD cell
patch-clamp electrophysiology data for the 3″- and 4″-
substituted isomers were similar, we examined only the 3″-
substituted derivatives. Using cortical neurons, we also
evaluated several (R)-A compounds with 3″-polar, protic R-
substituents (R = N(H)C(O)CH3, CO2H, NH3
+Cl−) to try to
correlate their activities on VGSCs with their diminished
anticonvulsant activities.
First, we determined the ability of the (R)-A derivatives with
a 3″-polar, aprotic R-substituent ((R)-3, (R)-5, (R)-7, (R)-8,
(R)-10, (R)-11) to modulate the VGSC transition to a slow-
inactivated state. Cortical cells were held at −70 mV and
conditioned to potentials ranging from −100 to +20 mV (in
+10 mV increments) for 5 s. Then fast-inactivated channels
were allowed to recover for 1000 ms at a hyperpolarized pulse
to −70 mV, and the fraction of channels available was tested by
a single depolarizing pulse, to −10 mV, for 20 ms (Figure 5A,
left). The hyperpolarization pulse allows channel recovery from
fast inactivation while limiting recovery from slow inactivation.
Representative traces that illustrate the extent of slow
inactivation observed at −50 mV are compared with the
prepulse at −100 mV in the absence or presence of (R)-5 in
Figure 5A, with complete slow inactivation curves (normalized
peak vs prepulse potential) shown in Figure 5B. For the 0.1%
DMSO (control) treated cells (−50 mV), 0.82 ± 0.03 fractional
unit (n = 5) of the Na+ current was available, suggesting a small
fraction (0.18 ± 0.03, calculated as 1 minus the normalized INa)
of the channels transitioned to a nonconducting (slow-
inactivated) state (Figure 5B,C). Compared with control
(0.1% DMSO), all of the 3″-polar, aprotic substituted (R)-A
compounds at 10 μM caused signiﬁcant increase in the maximal
fraction of current unavailable by depolarization, with maximal
induction observed in the presence of (R)-11: 0.82 ± 0.02 (n =
5; p < 0.01, Mann−Whitney U test). The eﬀectiveness of these
(R)-A compounds to promote slow inactivation in cortical
neurons at 10 μM approximated the IC50 values observed for
slow inactivation in CAD cells where the order of potency was
(R)-5, (R)-8 > (R)-11 > (R)-7, (R)-10 > (R)-3 (Figure 2,
Table 1). When we tested the (R)-A derivatives with a 3″-polar,
protic R-substituent ((R)-13, (R)-15, (R)-16), only (R)-15
caused an increase in the extent of slow inactivation
(Supporting Information, Figure S4A,C,E) while neither (R)-
13 nor (R)-16 (Supporting Information, Figure S4B,E) was
diﬀerent from 0.1% DMSO (control) treated neurons.
We next asked if the (R)-A derivatives that contained a 3″-
polar R-substituent that was either aprotic ((R)-3, (R)-5, (R)-6,
(R)-7, (R)-8, (R)-10, (R)-11) or protic ((R)-13, (R)-15, (R)-
16) could enhance steady-state fast inactivation. To investigate,
we used a protocol (Figure 6A, left) designed to induce a fast-
inactivated state, similar to that previously described.42 Neurons
were held at −70 mV, stepped to inactivating prepulse
potentials ranging from −120 to −10 mV (in 10 mV
increments) for 500 ms. Then the cells were stepped to 0
mV for 20 ms to measure the available current. A 500 ms
conditioning pulse was used because it allowed all of the
endogenous channels to transition to a fast-inactivated state at
all potentials assayed. Steady-state, fast inactivation curves of
Na+ currents (representative family of control current traces
shown in Figure 6B, left) from control (0.1% DMSO) treated
and (R)-3-, (R)-5-, (R)-6-, (R)-7-, (R)-8-, (R)-10-, and (R)-11-
treated cortical neurons were well ﬁtted with a single
Boltzmann function (R2 > 0.983 for all conditions). The V1/2
inactivation value for 0.1% DMSO-treated cells was −53.2 ±
1.2 mV (n = 4), which was signiﬁcantly diﬀerent from that of
(R)-5 (−59.9 ± 3.1 mV; n = 5), (R)-7 (−58.3 ± 1.4 mV; n =
4), and (R)-11 (−60.1 ± 1.2 mV; n = 5) treated cells (p < 0.05
vs control (0.1% DMSO); Student’s t-test; Figure 6C,D); none
of the other compounds ((R)-3, (R)-6, (R)-8, (R)-10) were
diﬀerent from controls (0.1% DMSO). The slope values were
unchanged between control and any of the conditions tested.
By comparison, we did not see evidence to indicate that the
(R)-A compounds with 3″-polar, protic R-substituents, (R)-13,
(R)-15, and (R)-16, aﬀected V1/2 or k values of steady-state fast
inactivation (Figure 6D).
Next, we tested whether (R)-A compounds that contained
polar R-substituents, aprotic or protic, at the 3″-position could
alter voltage-dependent activation properties of Na+ currents in
cortical neurons. Compound-treated cortical neuron activation
changes were measured by whole-cell ionic conductances by
comparing their midpoints (V1/2) and slope factors (k) in
response to command voltage changes (Figure 6A, right).
Representative traces for the 0.1% DMSO-treated neurons
(control) in response to the voltage protocol are shown in
Figure 6B (right). Boltzmann ﬁts for DMSO (control) and the
(R)-A compounds with polar, aprotic and polar, protic R-
substituents are shown in Figure 6C and Figure 6D,
respectively. The V1/2 value for steady-state activation for
0.1% DMSO-treated (control) neurons was −27.3 ± 3.3 mV (n
= 5), which was signiﬁcantly diﬀerent from those of (R)-5
(−37.5 ± 4.9 mV; n = 5), (R)-10 (−35.4 ± 5.4 mV; n = 5),
(R)-11 (−33.2 ± 1.9 mV; n = 4), (R)-13 (−39.0 ± 2.6 mV; n =
4), (R)-15 (−36.8 ± 3.0 mV; n = 5), and (R)-16 (−33.4 ± 3.2
mV; n = 5) (p < 0.05 vs control; Student’s t-test; Figure 6C,D).
The hyperpolarizing shifts induced by these compounds
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm500707r | J. Med. Chem. 2014, 57, 6165−61826174
suggest that in the presence of the compounds, NaV currents
are likely to activate earlier (i.e., at less-depolarized potentials).
Finally, we tested whether the (R)-A derivatives containing
polar R-substituents, aprotic or protic, at the 3″-position could
aﬀect frequency (use) dependent block of Na+ currents. Unlike
the data obtained with CAD cells, none of the compounds
tested at a 10 μM concentration in cortical neurons aﬀected
frequency (use) dependent block of Na+ currents, compared
with controls (0.1% DMSO) (Supporting Information, Figure
S5).
C. (R)-N-(3″-Chlorobiphenyl-4′-yl)methyl (R)-2-Acetamido-
3-methoxypropionamide ((R)-5) in HEK293 Cells. In order to
assess the relative eﬀect of an (R)-A compound on Na+ channel
isoforms, we examined the Na+ currents in HEK293 cells that
stably express CNS (hNaV1.1 and rNaV1.3), peripheral nervous
system (hNaV1.7), or cardiac (hNaV1.5) isoforms. Compound
(R)-5 (10 μM) was chosen for study because it displayed
excellent anticonvulsant activity in mice (ip) and rats (po)
(Table 1), and it modulated Na+ currents in CAD cells and rat
embryonic cortical neurons.
Properties of slow inactivation, fast inactivation, steady-state
activation, and frequency (use) dependent inhibition were
examined in the four cell lines using voltage protocols
illustrated in Figure 7A,K. The results from these experiments
are summarized in Table 2. Notably, (R)-5 exhibited similar,
but not identical, eﬀects on these biophysical properties
irrespective of Na+ channels, indicating that this compound
exhibited little isoform speciﬁcity. We observed that (R)-5
transitioned the four Na+ channel subtypes to the slow-
inactivated state and that diﬀerences were observed in the
degree to which (R)-5 aﬀected Na+ channel fast inactivation,
fast activation, and the frequency (use) inhibition of Na+
currents.
■ DISCUSSION
Recently, we merged the structures of functionalized amino
acids (FAAs)1,7−9 and α-aminoamides (AAAs),43 two classes of
compounds that have shown excellent anticonvulsant activities
in seizure models, to give compounds (R)-B and reported on
their anticonvulsant activities (Figure 8).11 The substituted (R)-
A compounds described herein are examples of (R)-B where R′
is a methoxymethyl moiety (R′ = CH2OCH3) and the X-Y-Z
unit is a single bond; they are also 4′-aryl derivatives of (R)-1.
In 2010, we showed that the unsubstituted N-(biphenyl-4′-
yl)methyl derivative (R)-2 exhibited excellent anticonvulsant
activity but that seizure protection in mice and rats was
accompanied by appreciable neurotoxicity (Figure 1, Table 1;
MES ED50 (mg/kg), 8.0 (mice, ip), 2.0 (rat, po); TD50 (mg/
kg), 11 (mice, ip), 49 (rat, po)).10 Subsequently, we showed
that the corresponding 3″-F-substituted analogue (R)-3
retained high anticonvulsant activity but that neurotoxicity
was reduced (Figure 1, Table 1; MES ED50 (mg/kg), 12 (mice,
ip), 2.4 (rat, po); TD50 (mg/kg), 50 (mice, ip), rat >500 (rat,
po)).11 While the PI value in mice for (R)-3 was higher than for
(R)-2, it was still below that of the ASD (R)-1 (PI (mice, ip):
(R)-2, 1.4; (R)-3, 4.1; (R)-1, 6.0).1 In this study, we explored
the eﬀect of the terminal aryl R-substituent in (R)-A on
anticonvulsant activity, neurotoxicity, and Na+ channel
function.
We found that the placement of polar, aprotic R-substituents
on the terminal aryl ring of (R)-A provided compounds with
excellent anticonvulsant activities and that these activities were
only modestly aﬀected by the site of aryl substitution (3″ vs
4″). In addition, we found that several (R)-A derivatives with
polar, aprotic R-substituents had improved PI values over (R)-2
(PI = 1.4) but that the PI values varied with the R-substituent
and the site of substitution. For the 3″-Cl and 4″-Cl derivatives
Figure 6. Eﬀects of (R)-A compounds with a polar, aprotic or a polar,
protic substituent at the 3″-position on fast inactivation and steady-
state activation states of Na+ currents in cortical embryonic neurons.
(A) Voltage protocol for fast inactivation (left) and activation (right).
(B) Representative family of currents in response to these protocols is
illustrated. (C, D) Representative Boltzmann ﬁts for steady-state fast
inactivation and activation for cortical neurons treated with 0.1%
DMSO (control) and various concentrations of the indicated
compounds are shown. Values for V1/2, the voltage of half-maximal
inactivation and activation, and the slope factors (k) were derived from
Boltzmann distribution ﬁts to the individual recordings and were
averaged to determine the mean (±SEM) voltage dependence of
steady-state inactivation and activation, respectively. Statistically
signiﬁcant diﬀerences between control and fast inactivation or
activation are indicated by asterisks (p < 0.05, one-way ANOVA).
Data are from ﬁve to eight cells per condition.
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Figure 7. Analysis of (R)-5 on electrophysiological properties of NaV1.1, NaV1.3, NaV1.7, and NaV1.5 currents in HEK293 cells. (A, K) Voltage
protocols for examining slow inactivation, fast inactivation, activation, and frequency (use) dependent block. NaV1.5 uses hyperpolarized protocols
because of diﬀerences in the hyperpolarized activation of this isoform. (B, E, H, L) Summary of steady-state slow-activation curves for HEK293 cells
treated with 0.1% DMSO (control) or 10 μM (R)-5. Insets illustrate representative current traces from HEK293 cells in the absence (control, 0.1%
DMSO) or presence of 10 μM (R)-5. The black and colored traces represent the currents evoked at −120 and −50 mV, respectively (highlighted in
the voltage protocol). (C, F, I, M) Representative Boltzmann ﬁts for steady-state fast inactivation and activation for HEK293 cells treated with 0.1%
DMSO (control) or 10 μM (R)-5. Values for V1/2, the voltage of half-maximal inactivation and activation, and the slope factors (k) were derived
from Boltzmann distribution ﬁts to the individual recordings and were averaged to determine the mean (±SEM) voltage dependence of steady-state
inactivation and activation, respectively. (D, G, J, N) Summary of average frequency (use) dependent decrease in current amplitude over time
(±SEM) produced by control (0.1% DMSO) or 10 μM (R)-5. Data are from ﬁve to six cells per condition.
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((R)-5, (R)-6), high PI values were obtained regardless of the
site of substitution (PI (mice, ip): (R)-5 (3″), 7.6; (R)-6 (4″),
6.8) and that the values exceeded that of (R)-2 (PI = 1.4) and
even (R)-1 (PI = 6.0). Correspondingly, for the 3″- and 4″-F
derivatives ((R)-3, (R)-4) and the 3″- and 4″-OCF3
compounds ((R)-11, (R)-12), high PI values were observed
for only the 3″-substituted isomers (PI (mice, ip): (R)-3 (3″-
F), 4.1; (R)-4 (4″-F), 1.8; (R)-11 (3″-OCF3), 4.9; (R)-12 (4″-
OCF3), 2.0). Correspondingly, when a polar, protic R-
substituent was placed in the terminal aryl ring in (R)-A to
give (R)-13−(R)-16, we observed minimal or no anticonvul-
sant activity. Accompanying this loss of activity was a reduction
in neurotoxicity, suggesting that the activity loss resulted from
either reduced levels of these compounds in the CNS or a
reduced interaction with the receptor(s) responsible for the
seizure protection and toxicity or both. When we tested
whether (R)-13, (R)-15, and (R)-16 modulated Na+ currents in
rat embryonic cortical neurons, only (R)-15 (R = 3″-CO2H)
displayed notable activity (Supporting Information, Figure S4).
This latter ﬁnding indicated that the diminished anticonvulsant
activities for (R)-13 and (R)-16 may have resulted, in part,
from their inability to promote Na+ channel slow inactivation
during the seizure test.
Both FAAs7−9 and AAAs44 likely exert their anticonvulsant
activities by interacting with Na+ channels. The FAA, (R)-1, has
been shown to preferentially promote the transition of Na+
channels to the slow inactivation state without aﬀecting fast
inactivation.7−9 We demonstrated that (R)-3 displayed potent
Na+ channel slow inactivation in CAD cells that exceeded (R)-1
(IC50 (μM): (R)-3, 2.9; (R)-1, 85).
15 Moreover, (R)-3
displayed notable frequency (use) dependent inhibition of
Na+ currents at concentrations (15 μM) above its IC50 value
(Figure 4B).15 In this study, we determined the Na+ channel
properties of the (R)-A compounds in three diﬀerent cell types
(CAD cells, rat embryonic cortical neurons, HEK293-trans-
fected cells). Overall, we found it diﬃcult to compare the
eﬀects of individual (R)-A compounds across the diﬀerent cell
systems. For several compounds, we observed diﬀerences in the
three cell types in their ability to aﬀect Na+ channel fast
inactivation and fast activation and frequency (use) inhibition
of Na+ currents. We have tentatively attributed these diﬀerences
to the diﬀerent channel compositions, expression levels,
auxiliary proteins, and origins (mouse, rat, human) in the
CAD, cortical, and HEK293 cell systems and the test (R)-A
concentrations used in the studies. Accordingly, the exper-
imental results in any given cell system were used to identify
interesting compounds, and direct comparisons were only
made within data sets from the same cell type.
We found that (R)-4−(R)-8 and (R)-10−(R)-12, com-
pounds that contained polar, aprotic R-substituents, potently
transitioned CAD cell Na+ channels to the slow-inactivated
state (IC50 = 0.12−2.9 μM) and that Na+ channel fast
inactivation was not observed (Figures 2, 3; Supporting
Information Figures S1, S2). Furthermore, we observed that
many compounds ((R)-4−(R)-6, (R)-10, (R)-11) showed
frequency (use) dependent inhibition of Na+ currents, provided
that concentrations higher than the slow inactivation IC50 value
were employed (Figure 4; Supporting Information, Figure S3).
We9 and others7 have not observed notable frequency (use)
inhibition of Na+ currents for (R)-1 at 100 μM. Our ﬁnding
Table 2. Comparative Current Densities, Cell Capacitances, and Boltzmann Parameters of Voltage Dependence of Channel
Activation and Steady-State Fast Inactivation Curves for Control-Treated and (R)-N-(3″-Chlorobiphenyl-4′-yl)methyl 2-
Acetamido-3-methoxypropionamide ((R)-5) Treated HEK293 Cells Expressing NaV1.1, NaV1.3, NaV1.7, or NaV1.5 Channels
a
voltage dependence of activationc voltage dependence of fast inactivation
condition
extent of slow
inactivation
(at −50 mV)b V1/2 (mV)
slope
(mV/e-fold) V1/2 (mV) slope (mV/e-fold)
use-dependent
inhibitiond
NaV1.1
control 0.17 ± 0.04 (6) −24.29 ± 1.52 (5) 4.92 ± 0.60 (5) −64.29 ± 3.63 (6) 4.93 ± 1.48 (6) 1.02 ± 0.08 (5)
10 μM (R)-5 0.77 ± 0.03 (6)* −22.43 ± 2.94 (6) 4.34 ± 1.78 (5) −70.00 ± 4.67 (6) 6.21 ± 2.11 (6) 0.81 ± 0.07 (6)*
NaV1.3
control 0.04 ± 0.02 (5) −29.56 ± 4.94 (5) 4.07 ± 1.96 (5) −65.39 ± 7.77 (5) 5.55 ± 1.28 (5) 1.12 ± 0.19 (5)
10 μM (R)-5 0.71 ± 0.09 (5)* −25.44 ± 2.01 (4) 4.47 ± 1.56 (4) −63.39 ± 7.01 (5) 6.81 ± 2.67 (5) 1.03 ± 0.18 (5)
NaV1.7
control 0.07 ± 0.04 (5) −27.15 ± 4.01 (5) 3.61 ± 1.24 (5) −61.09 ± 2.99 (5) 4.83 ± 1.12 (5) 1.03 ± 0.09 (5)
10 μM (R)-5 0.80 ± 0.03 (5)* −27.27 ± 1.98 (5) 4.21 ± 1.43 (5) −78.01 ± 3.69 (5)* 5.52 ± 1.98 (5) 0.92 ± 0.06 (5)
NaV1.5
control 0.18 ± 0.04 (5) −55.67 ± 3.19 (5) 3.16 ± 1.75 (5) −96.52 ± 1.60 (5) 5.34 ± 0.87 (4) 1.05 ± 0.16 (5)
10 μM (R)-5 0.80 ± 0.03 (5)* −57.12 ± 4.71 (5) 3.69 ± 1.69 (7) −109.11 ± 1.76 (5) 8.92 ± 0.82 (7)* 0.62 ± 0.31 (5)
aN values are indicated in parentheses. The protocols used for these parameters are illustrated in Figure 7. Asterisks represent statistically signiﬁcant
diﬀerences compared to control within each tested group (p < 0.05, Student’s t test). bThe extent of slow inactivation was calculated as 1 minus the
normalized peak INa and denotes the fraction of channels that have transitioned to a nonconducting (slow-inactivated) state at −50 mV. cValues for
V1/2, the voltage of half-maximal activation, and slope were derived from Boltzmann distribution ﬁts to the individual recordings and averaged to
determine the mean and standard error of the mean (±SEM). dFraction of current remaining at the end of the 30-pulse train, normalized to the ﬁrst
pulse.
Figure 8. Overlay of pharmacophores in FAAs and AAAs to give (R)-
B.
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that frequency (use) inhibition for selected (R)-A compounds
was observed only at concentrations ≥5-fold higher than their
slow inactivation IC50 values in CAD cells led us to retest (R)-1
at concentrations above its IC50 value (85 μM). At 500 μM
(R)-1, we observed noticeable frequency (use) inhibition of
Na+ currents (Figure 9) similar to that seen for the (R)-A
compounds (Figure 4). Signiﬁcantly, this concentration is
higher than the reported human therapeutic (R)-1 plasma
concentrations (20−50 μM),45 suggesting that frequency (use)
inhibition of Na+ currents may not be a clinically important
pathway for its drug function. In contrast, we found that several
substituted (R)-A derivatives, at low micromolar concentra-
tions, promoted Na+ channel slow inactivation and frequency
(use) dependent inhibition of Na+ currents. This ﬁnding
provides a potential comparative pharmacological advantage for
these compounds, since both mechanisms are proven pathways
to control neuronal hyperexcitability in the epileptic
neuron.7−9,39
To better approximate CNS VGSC activities, we tested many
of the (R)-A compounds with a 3″-polar, aprotic R-substituent
in rat embryonic cortical neurons that expressed the NaV1.1,
NaV1.2, NaV1.3, and NaV1.6 channels. We observed that (R)-3,
(R)-5, (R)-7, (R)-8, (R)-10, and (R)-11 all promoted slow
inactivation at 10 μM (Figure 5) and their relative eﬀectiveness
mirrored the slow inactivation IC50 values measured in CAD
cells (Figure 2). Diﬀerences were found between the cortical
neurons and the CAD cells on the ability of these compounds
to aﬀect fast inactivation and their ability to inhibit frequency
(use) dependent inhibition of Na+ currents (Figures 3, 4, 6;
Supporting Information, Figure S5). We have not explored the
factors that contributed to these diﬀerences.
There are nine Na+ channel isoforms. Despite structural
similarity, the isoforms’ distribution and biophysical properties
(e.g., kinetics of activation and inactivation, voltage, and
frequency (use) dependency) are distinct, each having speciﬁc
functions.39,41,46 Thus, we evaluated (R)-5 in HEK293 cells
expressing hNaV1.1, rNaV1.3, hNaV1.5, or hNaV1.7 channels.
The patch-clamp electrophysiology protocols for the cells
containing hNaV1.5 were diﬀerent from those used for hNaV1.1,
rNaV1.3, and hNaV1.7 (Figure 7A,K). We found that 10 μM
(R)-5 transitioned the Na+ channels to the slow-inactivated
state regardless of channel type (Figure 7B,E,H,L). Corre-
spondingly, diﬀerences in the fast inactivation proﬁles were
observed for the four isoforms. Compound (R)-5 did not aﬀect
rNaV1.3 fast inactivation compared with 0.1% DMSO (control),
while a depolarizing shift was found for the hNaV1.1-, hNaV1.5-,
and hNaV1.7-transfected cells, with the most pronounced shift
observed in hNaV1.7-expressing cells (Figure 7C,F,I,M).
Finally, we observed notable frequency (use) inhibition of
Na+ currents for the transfected hNaV1.5 cells (Figure 7N),
lesser amounts for the hNaV1.1- and hNaV1.7-expressing cells
(Figure 7D,J), and no inhibition for the rNaV1.3-expressing
cells (Figure 7G). Together these ﬁndings showed that (R)-5,
and perhaps the other polar, aprotic R-substituted (R)-A
derivatives, displayed little Na+ channel isoform speciﬁcity.
Rather, (R)-5 appears to act as a functionally selective Na+
channel inhibitor47 that controls hyperexcitability upon
excitation by transitioning a greater fraction of Na+ channels
to their slow-inactivated state and by inhibiting Na+ currents in
a frequency (use) dependent manner.
■ CONCLUSIONS
The successful merger of FAAs and AAAs (Figure 8) provided
substituted N-(biphenyl-4′-yl)methyl (R)-2-acetamido-3-me-
thoxypropionamide derivatives ((R)-A). Select (R)-A com-
pounds displayed low ED50 values and high PI values that, in
rodents, compared favorably with most clinical ASDs. We
found compounds that potently transitioned Na+ channels into
the slow-inactivated state and displayed frequency (use)
inhibition of Na+ currents at low micromolar concentrations.
The activities of (R)-As along with their pharmacokinetic
properties are being investigated further.
■ EXPERIMENTAL SECTION
General Methods. Melting points were determined in open
capillary tubes using a Thomas-Hoover melting point apparatus and
are uncorrected. Optical rotations were obtained on a Jasco P-1030
polarimeter at the sodium D line (589 nm) using a 1 dm path length
cell. NMR spectra were obtained at 400 MHz (1H) and 100 MHz
(13C) using TMS as an internal standard. Chemical shifts (δ) are
reported in parts per million (ppm) from tetramethylsilane. Low-
resolution mass spectra were obtained with a BioToF-II-Bruker
Daltonics spectrometer by Dr. S. Habibi at the University of North
Carolina, Department of Chemistry. The high-resolution mass
spectrum was performed on a Bruker Apex-Q 12 Telsa FTICR
spectrometer by Dr. S. Habibi. Microanalyses were performed by
Atlantic Microlab, Inc. (Norcross, GA). Reactions were monitored by
analytical thin-layer chromatography (TLC) plates (Aldrich, catalog
no. Z12272-6) and analyzed with 254 nm UV light. The mixtures were
puriﬁed by ﬂash column chromatography using silica gel (Dynamic
Adsorbents Inc., catalog no. 02826-25). All chemicals and solvents
were reagent grade and used as obtained from commercial sources
without further puriﬁcation. Yields reported are for puriﬁed products
and were not optimized. Compounds were checked by TLC, 1H and
13C NMR, MS, and elemental analyses. The analytical results are
within ±0.40% of the theoretical value. The NMR and the analytical
data conﬁrmed that the purity of the products was ≥95%.
General Procedure for the Deprotection and Acetylation of
(R)-N-(Biphenyl-4-yl)methyl 2-N-(tert-Butoxycarbonyl)amino-
3-methoxypropionamide Derivatives (Method 1). A CH2Cl2
solution (0.1−0.3 M) of the (R)-N-(biphenyl-4-yl)methyl 2-N-(tert-
butoxycarbonyl)amino-3-methoxypropionamide derivative was treated
with 4 M HCl in dioxane (3−4 equiv) at room temperature (2−6 h).
The reaction mixture was evaporated in vacuo. The resulting residue
was dissolved in CH2Cl2 (0.1−0.3 M), and then triethylamine (2−3
Figure 9. Eﬀect of (R)-1 in CAD cells on frequency (use) dependent
block. Summary of average frequency (use) dependent current
amplitude decrease (±SEM) produced by control (0.1% DMSO) or
by the presence of various concentrations of (R)-1 is shown (p > 0.05,
one-way ANOVA with Dunnett’s post hoc test). Concentrations
greater than 500 μM (R)-1 caused a signiﬁcant inhibition of use-
dependence starting at about pulse 8 (p < 0.05, one-way ANOVA with
Dunnett’s post hoc test). Data are from four to six cells per condition.
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equiv) and acetyl chloride (1.0−1.2 equiv) were carefully added at 0
°C. The resulting solution was stirred at room temperature (2−4 h).
The resulting solution was washed with an aqueous 10% citric acid
solution followed by a saturated aqueous NaHCO3 solution. The
organic layer was dried (Na2SO4) and concentrated in vacuo. The
residue was puriﬁed by column chromatography on SiO2 and/or
recrystallized with EtOAc/hexanes.
(R)-N-(4″-Fluorobiphenyl-4′-yl)methyl 2-Acetamido-3-me-
thoxypropionamide ((R)-4). Using method 1, (R)-56 (3.17 g, 7.9
mmol) and 4 M HCl (6.90 mL, 27.6 mmol) followed by Et3N (2.42
mL, 17.3 mmol) and AcCl (0.61 mL, 8.7 mmol) gave (R)-4 as a white
solid (2.50 g, 92%): Rf = 0.40 (MeOH/CH2Cl2 1/20); mp 189−190
°C; [α]26D −17.8° (c 1.0, CHCl3); 1H NMR (CDCl3) δ 2.04 (s, 3H),
3.40 (s, 3H), 3.44−3.48 (m, 1H), 3.83 (dd, J = 3.9, 9.0 Hz, 1H), 4.45−
4.59 (m, 3H), 6.43−5.46 (br d, 1H), 6.81−6.85 (m, 1H), 7.12 (t, J =
8.6 Hz, 2H), 7.32 (d, J = 7.6 Hz, 2H), 7.49−7.54 (m, 4H); addition of
excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-4 gave only
one signal for the acetyl methyl and one signal for the ether methyl
protons; 13C NMR (DMSO-d6) δ 22.6, 41.8, 52.7, 58.2, 72.1, 115.7 (d,
J = 21.3 Hz, 2C), 126.5, 127.6, 128.5 (d, J = 8.0 Hz, 2C), 136.4 (d, J =
2.9 Hz), 137.6, 138.6, 161.8 (d, J = 242.4 Hz), 169.5, 169.8; LRMS
(ESI+) 367.1 [M + Na]+ (calcd for C19H21FN2O3Na
+ 367.1). Anal.
(C19H21FN2O3) C, H, F, N.
(R)-N-(3″-Chlorobiphenyl-4′-yl)methyl 2-Acetamido-3-me-
thoxypropionamide ((R)-5). Using method 1, (R)-57 (4.00 g, 9.6
mmol) and 4 M HCl (8.36 mL, 33.4 mmol) followed by Et3N (2.93
mL, 21.0 mmol) and AcCl (0.74 mL, 10.5 mmol) gave (R)-5 as a
white solid (2.85 g, 83%): Rf = 0.40 (MeOH/CH2Cl2 1/20); mp 172−
173 °C; [α]26D −15.8° (c 1.1, CHCl3); 1H NMR (CDCl3) δ 2.00 (s,
3H), 3.37 (s, 3H), 3.49 (dd, J = 7.0, 9.0 Hz, 1H), 3.78 (dd, J = 4.0, 9.0
Hz, 1H), 4.43 (1/2HH′q, J = 5.8, 15.0 Hz, 1H), 4.49 (1/2HH′q, J =
5.8, 15.0 Hz, 1H), 4.62−4.67 (m, 1H), 6.71 (d, J = 6.8 Hz, 1H), 7.15−
7.18 (m, 1H), 7.30−7.52 (m, 8H); addition of excess (R)-
(−)-mandelic acid to a CDCl3 solution of (R)-5 gave only one signal
for the acetyl methyl and one signal for the ether methyl protons; 13C
NMR (CDCl3) δ 23.3, 43.3, 52.7, 59.2, 72.1, 125.3, 127.3, 127.5,
128.1, 130.2, 134.8, 137.9, 139.1, 142.6, 170.3, 170.6; the remaining
aromatic peak was not detected and is believed to overlap with the
observed signals; LRMS (ESI+) 383.1 [M + Na]+ (calcd for
C19H21ClN2O3Na
+ 383.1). Anal. (C19H21ClN2O3) C, H, Cl, N.
(R)-N-(4″-Chlorobiphenyl-4′-yl)methyl 2-Acetamido-3-me-
thoxypropionamide ((R)-6). Using method 1, (R)-58 (2.80 g, 6.7
mmol), and 4 M HCl (6.70 mL, 26.7 mmol) followed by Et3N (2.10
mL, 14.7 mmol) and AcCl (0.52 mL, 7.4 mmol) gave (R)-6 as a white
solid (1.83 g, 76%): Rf = 0.40 (MeOH/CH2Cl2 1/20); mp 215−216
°C; [α]26D −16.9° (c 1.1, CHCl3); 1H NMR (CDCl3) δ 2.03 (s, 3H),
3.39 (s, 3H), 3.44−3.48 (m, 1H), 3.82 (dd, J = 4.0, 9.2 Hz, 1H), 4.45−
4.61 (m, 3H), 6.45−6.49 (br d, 1H), 6.86−6.91 (m, 1H), 7.32 (d, J =
8.0 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.48−7.52 (m, 4H); addition of
excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-6 gave only
one signal for the acetyl methyl and one signal for the ether methyl
protons; 13C NMR (CDCl3) δ 23.4, 43.4, 52.7, 59.3, 71.9, 127.5, 128.2,
128.5, 129.2, 133.7, 137.5, 139.3, 139.4, 170.3, 170.5; LRMS (ESI+)
361.2 [M + H]+ (calcd for C19H21ClN2O3H
+ 361.2). Anal.
(C19H21ClN2O3) C, H, Cl, N.
(R)-N-(3″-Bromobiphenyl-4′-yl)methyl 2-Acetamido-3-me-
thoxypropionamide ((R)-7). Using method 1, 4 M HCl in dioxane
(3.5 mL), (R)-59 (1.30 g, 2.8 mmol), Et3N (862 mg, 8.5 mmol), and
AcCl (268 mg, 3.4 mmol) gave compound (R)-7 as a white solid (620
mg, 54%): Rf = 0.44 (1:20 MeOH/CH2Cl2); mp 171−173 °C; [α]26 D
−17.3° (c 1.0, CHCl3); 1H NMR (CDCl3) δ 2.00 (s, 3H), 3.37 (s,
3H), 3.45−3.49 (m, 1H), 3.79 (dd, J = 4.0, 9.0 Hz, 1H), 4.40−4.55
(m, 2H), 4.56−4.66 (m, 1H), 6.60 (d, J = 6.4 Hz, 1H), 6.98−7.08 (br
s, 1H), 7.24−7.35 (m, 3H), 7.39−7.56 (m, 4H), 7.68 (s, 1H); addition
of excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-7 gave
only one signal for the acetyl methyl and one signal for the ether
methyl protons; 13C NMR (CDCl3) δ 23.1, 43.1, 52.5, 59.1, 71.8,
122.9, 125.6, 127.3, 127.9, 130.0, 130.2, 130.3, 137.6, 138.8, 142.7,
170.1, 170.3; LRMS (ESI+) 405.0 [M + H]+ (100%), 407.0 [M + 2 +
H]+ (100%); HRMS (ESI+) 405.0814 [M + H]+ (calcd for
C19H21
79BrN2O3H
+ 405.0814). Anal. (C19H21BrN2O3) C, H, Br, N.
(R)-N-(3″-Iodobiphenyl-4′-yl)methyl 2-Acetamido-3-me-
thoxypropionamide ((R)-8). Using method 1, 4 M HCl in dioxane
(2.0 mL), (R)-60 (670 mg, 1.3 mmol), Et3N (515 mg, 3.9 mmol), and
AcCl (123 mg, 1.6 mmol) gave compound (R)-8 as a white solid (515
mg, 87%): Rf = 0.41 (1:20 MeOH/CH2Cl2); mp 161−163 °C; [α]26D
−11.0° (c 1.0, CHCl3); 1H NMR (CDCl3) δ 2.05 (s, 3H), 3.41 (s,
3H), 3.43−3.50 (m, 1H), 3.84 (dd, J = 4.3, 9.3 Hz, 1H), 4.46−4.55
(m, 2H), 4.57−4.60 (m, 1H), 6.45 (d, J = 6.8 Hz, 1H), 6.83 (t, J = 4.8
Hz, 1H), 7.17 (t, J = 7.8 Hz, 1H), 7.34 (d, J = 8.2 Hz, 2H), 7.48−7.55
(m, 3H), 7.68 (d, J = 7.8 Hz, 1H), 7.92 (s, 1H); addition of excess (R)-
(−)-mandelic acid to a CDCl3 solution of (R)-8 gave only one signal
for the acetyl methyl and one signal for the ether methyl protons; 13C
NMR (CDCl3) δ 23.2, 43.2, 52.4, 59.1, 71.6, 94.8, 126.3, 127.4, 127.9,
130.4, 136.0, 136.2, 137.6, 138.9, 142.9, 170.0, 170.3; HRMS (ESI+)
453.0675 [M + H]+ (calcd for C19H21IN2O3H
+ 453.0673). Anal.
(C19H21IN2O3) C, H, I, N.
(R)-N-(3″-Cyanobiphenyl-4′-yl)methyl 2-Acetamido-3-me-
thoxypropionamide ((R)-9). Using method 1, (R)-61 (3.10 g, 7.6
mmol) and 4 M HCl (9.5 mL) followed by Et3N (2.30 g, 22.7 mmol)
and AcCl (0.71 g, 9.1 mmol) gave the desired product (R)-9 (2.00 g,
75%) as a white solid: Rf = 0.42 (CH2Cl2/CH3OH 19/1); mp 122−
123 °C; [α]24.5D −16.0° (c 1.0, CHCl3); 1H NMR (CDCl3) δ 2.03 (s,
3H), 3.40 (s, 3H), 3.47−3.52 (m, 1H), 3.79−3.84 (m, 1H), 4.48−4.54
(m, 2H), 4.59−4.63 (m, 1H), 6.56−6.59 (br d, 1H), 7.03−7.07 (br t,
1H), 7.36 (d, J = 8.4 Hz, 2H), 7.48−7.64 (m, 4H), 7.76−7.82 (m,
2H); addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of
(R)-9 gave only one signal for the acetyl methyl and one signal for the
ether methyl protons; 13C NMR (CDCl3) δ 23.4, 43.3, 52.7, 59.3, 71.9,
113.2, 119.0, 127.5, 128.3, 129.8, 130.8, 130.9, 131.6, 138.2, 138.5,
142.9, 170.4, 170.6; LRMS (ESI+) 352.2 [M + H]+ (calcd for
C20H22N3O3
+ 352.2); HRMS (ESI+) 352.1660 [M + H]+ (calcd for
C20H22N3O3
+ 352.1661). Anal. (C20H21N3O3) C, H, N.
(R)-N-(3″-Triﬂuoromethylbiphenyl-4′-yl)methyl 2-Acetami-
do-3-methoxypropionamide ((R)-10). Using method 1, 4 M HCl
in dioxane (3.0 mL), (R)-62 (1.34 g, 3.0 mmol), Et3N (896 mg, 8.9
mmol), and AcCl (348 g, 4.4 mmol) gave compound (R)-10 as a white
solid (1.02 g, 88%): Rf = 0.42 (1:20 MeOH/CH2Cl2); mp 161−162
°C; [α]24D −13.7° (c 1.0, CHCl3); 1H NMR (CDCl3) δ 2.03 (s, 3H),
3.40 (s, 3H), 3.49 (dd, J = 4.3, 9.3 Hz, 1H), 3.81 (dd, J = 4.3, 9.3 Hz,
1H), 4.45−4.58 (m, 2H) 4.61−4.64 (m, 1H), 6.58 (d, J = 7.0 Hz, 1H),
7.04 (t, J = 5.3 Hz, 1H), 7.36 (d, J = 8.2 Hz, 2H), 7.51−7.62 (m, 4H),
7.73 (d, J = 7.4 Hz, 1H), 7.80 (s, 1H); addition of excess (R)-
(−)-mandelic acid to a CDCl3 solution of (R)-10 gave only one signal
for the acetyl methyl and one signal for the ether methyl protons; 13C
NMR (CDCl3) δ 23.1, 43.1, 52.5, 59.1, 71.7, 123.7 (q, J = 4.0 Hz),
124.0 (q, J = 4.0 Hz), 124.1 (q, J = 272.0 Hz), 126.0, 127.4, 129.2,
130.2, 131.2 (q, J = 32.0 Hz), 137.9, 138.9, 141.4, 170.1, 170.4; MS
(ESI+) 395.2 [M + H]+ (calcd for C20H22F3N2O3
+ 395.2); HRMS
(ESI+) 395.1583 [M + H]+ (calcd for C20H22F3N2O3
+ 395.1582).
Anal. (C20H21F3N2O3) C, H, F, N.
(R)-N-(3″-Triﬂuoromethoxybiphenyl-4′-yl)methyl 2-Acet-
amido-3-methoxypropionamide ((R)-11). Using method 1, (R)-
63 (2.14 g, 4.6 mmol) and 4 M HCl (4.00 mL, 16.0 mmol) followed
by Et3N (1.40 mL, 10.1 mmol) and AcCl (0.36 mL, 5.0 mmol) gave
(R)-11 as a white solid (1.69 g, 90%): Rf = 0.40 (MeOH/CH2Cl2 1/
20); mp 139−140 °C; [α]26D −13.5° (c 1.3, CHCl3); 1H NMR
(CDCl3) δ 2.03 (s, 3H), 3.40 (s, 3H), 3.47 (dd, J = 7.4, 9.2 Hz, 1H),
3.82 (dd, J = 4.0, 9.2 Hz, 1H), 4.46−4.61 (m, 3H), 6.49 (d, J = 6.4 Hz,
1H), 6.89−6.93 (m, 1H), 7.18−7.21 (m, 1H), 7.33−7.54 (m, 7H);
addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-
11 gave only one signal for the acetyl methyl and one signal for the
ether methyl protons; 13C NMR (DMSO-d6) δ 22.5, 41.7, 52.7, 58.2,
72.1, 119.1, 119.6, 120.1 (q, J = 254.9 Hz), 125.7, 126.7, 127.7, 130.8,
136.8, 139.5, 142.3, 149.0, 169.4, 169.8; LRMS (ESI+) 433.1 [M +
Na]+ (calcd for C20H21F3N2O4Na
+ 433.1). Anal. (C20H21F3N2O4) C,
H, F, N.
(R)-N-(4″-Triﬂuoromethoxybiphenyl-4′-yl)methyl 2-Acet-
amido-3-methoxypropionamide ((R)-12). Using method 1, (R)-
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64 (0.81 g, 1.7 mmol) and 4 M HCl (1.49 mL, 6.0 mmol) followed by
Et3N (0.53 mL, 3.8 mmol) and AcCl (0.13 mL, 1.9 mmol) gave (R)-
12 as a white solid (0.59 g, 84%): Rf = 0.40 (MeOH/CH2Cl2 1/20);
mp 194−195 °C; [α]26D −14.3° (c 0.9, CHCl3); 1H NMR (CDCl3) δ
2.02 (s, 3H), 3.39 (s, 3H), 3.48 (dd, J = 7.4, 9.2 Hz, 1H), 3.81 (dd, J =
4.0, 9.2 Hz, 1H), 4.45−4.55 (m, 2H), 4.58−4.63 (m, 1H), 6.56 (d, J =
6.4 Hz, 1H), 6.98−7.01 (m, 1H), 7.27 (d, J = 8.0 Hz, 2H), 7.33 (d, J =
8.0 Hz, 2H), 7.49−7.58 (m, 4H); addition of excess (R)-(−)-mandelic
acid to a CDCl3 solution of (R)-12 gave only one signal for the acetyl
methyl and one signal for the ether methyl protons; 13C NMR
(DMSO-d6) δ 22.5, 41.7, 52.7, 58.2, 72.1, 120.1 (q, J = 254.9 Hz,
OCF3), 121.4, 126.6, 127.7, 128.4, 137.1, 139.1, 139.3, 147.7, 169.4,
169.8; LRMS (ESI+) 433.1 [M + Na]+ (calcd for C20H21F3N2O4Na
+
433.1). Anal. (C20H21F3N2O4) C, H, F, N.
(R)-N-(3″-Acetylaminobiphenyl-4′-yl)methyl 2-Acetamido-3-
methoxypropionamide ((R)-13). Using method 1, (R)-65 (1.80 g,
4.1 mmol) and 4 M HCl (3.1 mL, 12.4 mmol) followed by Et3N (1.24
g, 12.2 mmol) and AcCl (0.38 g, 4.9 mmol) gave the desired product
(R)-13 (1.05 g, 71%) as a white powder: Rf = 0.20 (CH2Cl2/CH3OH
19/1); mp 150−151 °C; [α]24.5D +11.1° (c 1.0, CH3OH); 1H NMR
(CDCl3/CD3OD) δ 2.04 (s, 3H), 2.16 (s, 3H), 3.47 (s, 3H), 3.52−
3.57 (m, 1H), 3.68−3.73 (m, 1H), 4.40−4.52 (m, 2H), 4.54−4.60 (m,
1H), 7.29−7.40 (m, 4H), 7.50−7.56 (m, 3H), 7.76 (s, 1H); 13C NMR
(CDCl3/CD3OD) δ 22.8, 23.9, 43.1, 53.1, 59.1, 72.0, 118.6, 119.0,
122.8, 127.4, 127.9, 129.3, 137.1, 138.8, 140.3, 141.5, 170.4, 171.5; one
carbonyl resonance was not detected; LRMS (ESI+) 384.2 [M + H]+
(calcd for C21H26N3O3
+ 384.2); HRMS (ESI+) 384.1924 [M + H]+
(calcd for C21H26N3O3
+ 384.1923).
(R)-N-(3″-Hydroxymethylbiphenyl-4′-yl)methyl 2-Acetami-
do-3-methoxypropionamide ((R)-14). To a solution of (R)-73
(0.65 g, 1.6 mmol) in CH2Cl2 (16 mL) was added 4 M HCl in dioxane
(1.5 mL, 6.0 mmol), and the mixture was stirred at room temperature
(4 h). The reaction mixture was evaporated in vacuo and recrystallized
(CH3OH/EtOAc/hexanes) to give the desired product (R)-14 (0.51
g, 90%) as a white solid: Rf = 0.48 (CH2Cl2/CH3OH 9/1); mp 152−
153 °C; [α]22.5D +12.7° (c 1.0, CH3OH);
1H NMR (CDCl3/CD3OD)
δ 2.00 (s, 3H), 3.34 (s, 3H), 3.45−3.49 (m, 1H), 3.67−3.72 (m, 1H),
4.42−4.46 (m, 2H), 4.51−4.55 (m, 1H), 4.69 (s, 2H), 7.27−7.31 (m,
3H), 7.35−7.41 (m, 1H), 7.44−7.46 (m, 1H), 7.50−7.54 (m, 3H); 13C
NMR (CDCl3/CD3OD) δ 23.1, 43.3, 52.9, 59.3, 65.0, 72.0, 125.7,
126.1, 126.3, 127.5, 128.0, 129.1, 137.1, 140.4, 141.0, 141.8, 170.3,
171.2; LRMS (ESI+) 357.1 [M + H]+ (calcd for C20H24N2O4H
+
357.2). Anal. (C20H24N2O4) C, H, N.
(R)-N-(3″-Carboxybiphenyl-4′-yl)methyl 2-Acetamido-3-me-
thoxypropionamide ((R)-15). Using the previous procedure, (R)-74
(0.31 g, 0.7 mmol) and 4 M HCl (0.8 mL, 3.2 mmol) gave the desired
product (R)-15 (0.21 g, 82%) as a white solid: Rf = 0.56 (CH2Cl2/
CH3OH 9/1); mp 196−197 °C; [α]23D +9.6° (c 1.0, CH3OH); 1H
NMR (CDCl3/CD3OD) δ 1.99 (s, 3H), 3.46−3.50 (m, 1H), 3.63−
3.66 (m, 1H), 4.39 (dd, J = 5.8, 14.0 Hz, 1H), 4.46 (dd, J = 5.8, 14.0
Hz, 1H), 4.50−4.55 (br t, 1H), 6.78−6.84 (m, 1H), 7.16−7.21 (m,
1H), 7.28−7.56 (m, 8H); the methoxy proton resonance was not
detected and believed to be overlapped with the adjacent peak near δ
3.40; 13C NMR (CDCl3/CD3OD) δ 22.8, 43.1, 52.9, 59.1, 72.1, 127.4,
128.0, 128.4, 128.8, 128.9, 131.0, 131.5, 137.5, 139.4, 141.0, 168.9,
170.4, 171.5; LRMS (ESI+) 371.2 [M + H]+ (calcd for C20H22N2O5H
+
371.2); HRMS (ESI+) 371.1607 [M + H]+ (calcd for C20H22N2O5H
+
371.1607). Anal. (C20H22N2O5·0.13H2O) C, H, N.
(R)-N-(3″-Aminobiphenyl-4′-yl)methyl 2-Acetamido-3-me-
thoxypropionamide Hydrochloride ((R)-16). Using the procedure
for (R)-14, (R)-75 (1.18 g, 3.59 mmol) and 4 M HCl (2.7 mL, 10.8
mmol) gave the desired product (R)-16 (0.91 g, 90%) as a yellow
solid: Rf = 0.00 (EtOAc/hexanes 1/1); mp 99−100 °C; [α]23.5D +10.4
° (c 1.0, CH3OH); 1H NMR (CDCl3/CD3OD) δ 1.99 (s, 3H), 3.36
(s, 3H), 3.50 (dd, J = 4.0, 9.2 Hz, 1H), 3.78 (dd, J = 7.2, 9.2 Hz, 1H),
4.43 (dd, J = 5.8, 15.0 Hz, 1H), 4.48 (dd, J = 5.8, 15.0 Hz, 1H), 4.59−
4.64 (m, 1H), 6.63−6.67 (m, 2H), 6.85 (m, 1H), 6.93−6.96 (m, 1H),
6.99−7.05 (br t, 1H), 7.20 (t, J = 7.8 Hz, 1H), 7.26 (d, J = 6.0 Hz,
2H), 7.49 (dd, J = 1.6, 6.4 Hz, 2H); 13C NMR (CD3OD) δ 22.6, 42.8,
52.8, 58.3, 72.1, 121.2, 122.0, 126.0, 126.6, 127.8, 130.4, 132.8, 137.2,
139.5, 141.4, 169.6, 169.9; LRMS (ESI+) 364.2 [M + Na − HCl]+
(calcd for C19H23NaN3O3
+ 364.2); HRMS (ESI+) 342.1817 [M − Cl]+
(calcd for C19H24N3O3 342.1817).
Pharmacology. Compounds were screened under the auspices of
the National Institutes of Health’s ASP. Experiments were performed
in male rodents (albino Carworth Farms No. 1 mice (ip), albino
Sprague−Dawley rats (ip, po)). Housing, handling, and feeding were
in accordance with recommendations contained in the Guide for the
Care and Use of Laboratory Animals. Anticonvulsant activity was
established using the MES test,4 6 Hz,5 and the scMet test,23 according
to previously reported methods.1
Catecholamine A Diﬀerentiated (CAD) Cells. CAD cells were
grown at 37 °C and in 5% CO2 (Sarstedt, Newton, NC) in Ham’s
F12/EMEM (GIBCO, Grand Island, NY), supplemented with 8% fetal
bovine serum (Sigma, St. Louis, MO) and 1% penicillin/streptomycin
(100% stocks, 10 000 U/mL penicillin G sodium and 10 000 μg/mL
streptomycin sulfate).9,14 Cells were passaged every 6−7 days at a 1:25
dilution.
Cortical Neurons. Rat cortical neuron cultures were prepared
from cortices dissected from embryonic day 19 brains exactly as
described.48,49
Culturing HEK293 Cells Expressing NaV1.1, NaV1.3, NaV1.5,
and NaV1.7. The cDNA gene encoding NaV1.1 was codon-optimized
and synthesized using the open reading frame (accession no.
NC_000002.11) and subcloned into the vector pTarget. The cDNA
genes encoding NaV1.3 from rat and NaV1.7 from human were
subcloned into the vector pcDNA3.1-mod. The cDNA encoding
NaV1.5 from human
50 was introduced into pcDNA3.1(+) with the
CMV promoter. The constructs were then transfected into HEK293
cells using the calcium phosphate precipitation technique. After 48 h,
the cells were passaged into 100 mm dishes and treated with G418
(Geneticin, Life Technologies) at 800 μg/mL to select for neomycin
resistant cells. After 2 weeks, colonies were picked and split. The
colonies were then tested for channel expression with whole-cell
patch-clamp technique. The cell line was then maintained with 500
μg/mL G418. NaV1.1,
34 NaV1.3,
51 NaV1.5,
52 and NaV1.7
53 stable cells
were grown under standard tissue culture conditions (5% CO2 at 37
°C) in Dulbecco’s modiﬁed Eagle medium supplemented with 10%
fetal bovine serum.
Electrophysiology. Whole-cell voltage clamp recordings were
performed at room temperature on HEK293 cells, CAD cells, and
cortical neurons using an EPC 10 ampliﬁer (HEKA Electronics,
Lambrecht/Pfalz Germany). Electrodes were pulled from thin-walled
borosilicate glass capillaries (Warner Instruments, Hamden, CT) with
a P-97 electrode puller (Sutter Instrument, Novato, CA) such that ﬁnal
electrode resistances were 1−2 MΩ when ﬁlled with internal solutions.
The internal solution for recording Na+ currents contained the
following (in mM): 110 CsCl, 5 MgSO4, 10 EGTA, 4 ATP Na2-ATP,
25 HEPES (pH 7.2, 290−310 mOsm/L). The external solution
contained the following (in mM): 100 NaCl, 10 tetraethylammonium
chloride (TEA-Cl), 1 CaCl2, 1 CdCl2, 1 MgCl2, 10 D-glucose, 4 4-AP,
0.1 NiCl2, 10 HEPES (pH 7.3, 310−315 mOsm/L). Whole-cell
capacitance and series resistance were compensated with the ampliﬁer.
Series resistance error was always compensated to be less than ±3 mV.
Cells were considered only when the seal resistance was less than 3
MΩ. Linear leak currents were digitally subtracted by P/4.
Data Acquisition and Analysis. Signals were ﬁltered at 10 kHz
and digitized at 10−20 kHz. Analysis was performed using Fitmaster
and Origin8.1 (OriginLab Corporation, MA, USA). For activation
curves, conductance (G) through Na+ channels was calculated using
the equation G = I/(Vm − Vrev), where Vrev is the reversal potential, Vm
is the membrane potential at which the current was recorded, and I is
the peak current. Activation and inactivation curves were ﬁtted to a
single-phase Boltzmann function G/Gmax = 1/{1 + exp[(V − V50)/k]},
where G is the peak conductance, Gmax is the ﬁtted maximal G, V50 is
the half activation voltage, and k is the slope factor. Additional details
of speciﬁc pulse protocols are described in the results text or ﬁgure
legends.
Statistical Analyses. Diﬀerences between mean values were
compared by either paired or unpaired two-tailed Student’s t-tests or
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an analysis of variance (ANOVA), when comparing multiple groups
(repeated measures whenever possible). If a signiﬁcant diﬀerence was
determined by ANOVA, then a Dunnett’s or Tukey’s post hoc test was
performed. Data are expressed as the mean ± SEM, with p < 0.05
considered as the level of signiﬁcance.
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